Jun 09, 2020
Lupin Signs Marketing Agreement With Ceek for Women's Health Products to Improve OB/GYN and Patient Exam Experience
May 19, 2020
Amplyx Pharmaceuticals Advances Development of Novel Antifungal, Fosmanogepix
Mar 26, 2020
Citius Pharmaceuticals Announces Publication in Antimicrobial Agents and Chemotherapy Journal of Positive Preclinical Results for Mino-Lok® in Rapidly Eradicating Candida Auris
Mar 25, 2020
Global Candidiasis Pipeline Guide, H1 2020: Therapeutics Development & Assessment, Companies Involved, Drug Profiles, Dormant Projects, Discontinued Products
Feb 18, 2020
m8 Pharmaceuticals and Vectans Pharma signed an exclusive licensing agreement of Loramyc® (miconazole Lauriad®) for Mexico and Brazil
Feb 13, 2020
SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)
Feb 03, 2020
Global Invasive Fungal Infection (IFI) Market Report 2020 - Surging Demand for Low-Cost Pipeline Products, Increase in Use of Broad-Spectrum Antibiotics
Jan 08, 2020
U.S. FDA Approves Supplemental New Drug Application (sNDA) for Expanded Indication of MYCAMINE® (micafungin for injection) for the Treatment of Invasive Candidiasis in Pediatric Patients Less Than 4 Months of Age
Jan 08, 2020
SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
Dec 09, 2019
Autoimmune Technologies Announces New Subsidiary to Develop Novel Antibody and Allogeneic Somatic Stem Cell Therapeutics For the Treatment of Invasive Candidiasis and Other Infectious Disease
Dec 09, 2019
Stadius Biopharma to Present Data on Fully Human Antibodies for the Treatment of Candida Infections
Nov 06, 2019
NxGen MDx announces Urogenital Pathogens Tests with a turnaround of 24 hours
Oct 24, 2019
SCYNEXIS Expands FURI Protocol to a Broader Range of Refractory Serious Fungal Infections, Building on Ibrexafungerp's Positive Data and Favorable Toxicology Profile Observed to Date
Jul 24, 2019
SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study)
Jun 25, 2019
World-renowned Fungal Infection Expert Comments on Oral Ibrexafungerp Data Presented by SCYNEXIS at ASM Microbe 2019
May 06, 2019
SCYNEXIS Presents Data at ACOG 2019 Further Supporting a Future NDA Submission of Oral Ibrexafungerp for Vulvovaginal Candidiasis (VVC)
Apr 30, 2019
Caspofungin Market to Touch US$ 496.20 Million by 2027, Says TMR
Mar 14, 2019
SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update
Feb 28, 2019
SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019
Feb 07, 2019
The candidiasis drugs market will register a CAGR of almost 4% by 2023